SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: drdan who wrote (1485)	6/20/1998 2:53:00 PM
From: Andrew H	Read Replies (2) of 5402

Whoa, drdan! Didn't Baxter spend 150M to buy SMTG for their blood substitute product? Wasn't the purpose of that to replace HemAssist? I don't think it is correct to say they have "no product." They just bought an expensive new one. Now if your point is that the likely failure of HemAssist is good news for SGNC, I will have to agree with you. There are obviously a lot of problems with blood substitutes and bringin them to market. That is both good and bad for SGNC. However, as long as they are not ruled out as having a viable product, it is more good than bad. As you probably know, NFLD has a blood substitute product about to enter P3 trials with Upjohn as a partner. >>Baxter,who seem to be very focused on bringing a "blood substitute" to market,now have no product and have spent a ton of money to find this out ....it MAY be that they will look at products already in various phases of testing rather than start from scratch, and pher02 happens to be one such product, with a bit of promise,<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next